this was a retrospective study not a random clinical Trial and in addition there were a lot of problems getting all the demographic and co morbidity data for each patient; the study was completed in late June and has undergone enough peer review to make it to the NIH publication (which I think is a BIG DEAL), notwithstanding that, it adds to the growing case for HCQ
[NCBI.NIH]... patients under HCQ-AZ treatment for at least 3 days had a better clinical outcome, based on mortality rates among patients >60 years, less transfer to ICU and shorter length of stay at the hospital, and these patients also had a shorter duration of viral shedding than patients who did not receive this drug combination. Finally, a global strategy for the management of the COVID-19 outbreak may help to limit both the number of cases and fatalities and guide countries where this pandemic has not yet peaked.
[case fatality rate for people over 60 years old were 0.9% w/o HCQ, 0.5% w HCQ]
|